Carbohydrate deficient glycoprotein syndrome type II: a deficiency in Golgi localised N-acetyl-glucosaminyltransferase II

J Jaeken, H Schachter, H Carchon, P De Cock, B Coddeville, G Spik

Abstract
The carbohydrate deficient glycoprotein (CDG) syndromes are a family of genetic multisystemic disorders with severe nervous system involvement. This report is on a child with a CDG syndrome that differs from the classical picture but is very similar to a patient reported in 1991. Both these patients are therefore designated CDG syndrome type II. Compared with type I patients they have a more severe psychomotor retardation but no peripheral neuropathy or cerebellar hypoplasia. The serum transferrin isoform pattern obtained by isoelectric focusing showed disialotransferrin as the major fraction. The serum disialotransferrin, studied in the present patient, contained two moles of truncated monomannantennary Sialyl-Gal-GlcNAc-Man(α1→3)[Man(α1→6)]Man(β1→4)GlcNAc(β1→4)GlcNAc-Asn per mole of transferrin. A profoundly deficient activity of the Golgi enzyme N-acetylglycosaminyltransferase II (EC 2.4.1.143) was demonstrated in fibroblasts. (Arch Dis Child 1994; 71: 123–127)

Carbohydrate deficient glycoprotein (CDG) syndromes are genetic multisystemic diseases first reported in 1980 by Jaeken et al. They are characterised by a deficiency in the carbohydrate moiety of secretory glycoproteins, lysosomal enzymes, and probably also membranous glycoproteins (for reviews see Jaeken et al1–3). The nervous system is always moderately to severely affected and most other organs are involved to a variable degree. A reliable diagnostic test is isoelectric focusing of serum transferrin showing a cathodal shift as a consequence of the partial sialic acid deficiency.4 5 The primary defect has yet to be determined. Recently we have reported on a CDG syndrome in an Iranian girl with distinctive clinical and biochemical features.6 Here we describe a Belgian boy with remarkably similar findings. These two patients represent a separate variant of CDG syndrome designated type II as opposed to the ‘classic’ type I. We have demonstrated that the activity of UDP-GlcNAc: α-D-mannoside β1→2-N-acetylglycosaminyltransferase II (GnT II; EC 2.4.1.143) is severely decreased in patient fibroblasts thus identifying this disease as a Golgi disorder. A short report on this patient has been published elsewhere.7

Case report
The patient, a Belgian boy, was born in 1983 after a normal pregnancy and delivery. His birth weight was 3250 g, length 50 cm, and head circumference 35 cm. He had a younger healthy brother; the parents were not related. The father’s height was on the 3rd centile and head circumference on the 90th centile; he showed some facial dysmorphism with a short neck but was otherwise normal. From birth the patient was hypotonic. He showed dysmorphic features: a hook nose, large dysplastic ears in oblique position, thin lips, prognathia of the maxilla, short neck, proximal implantation of the thumbs, and irregular position of the toes. There was a cardiac murmur due to a small ventricular septal defect. Psychomotor development was severely retarded: visual contact appeared around 16 months (but remained poor), he could sit without support at 2–5 years, reach for an object at 4–5 years, and take a few steps without support at 7 years. At the age of 10 years his speech was limited to a few monotonous sounds. Growth was normal until the age of 2 years but then progressively slowed down; at 10 years his height was 114 cm (3rd centile 125 cm, weight 18 kg (3rd centile 23 kg), and his head circumference has remained between the 25th and 50th centiles. From the first weeks he suffered from gastrointestinal problems (regurgitation due to volvulus of the stomach, and obstipation) as well as from frequent infections particularly of the upper airways. Epilepsy developed at the age of 6 years and was only partially controlled by methylphenobarbitone and sodium valproate. He showed a striking stereotypic behaviour: hand-mouth and handwashing movements, head turning, knocking on his cheeks, and rocking. After the age of 1 year other morphological characteristics were noted: a midfrontal capillary haemangioma, gum hypertrophy and unusually large teeth, thoracolumbar kyphoscoliosis, hollowed breast, hypotrophic distal limbs, and flat feet. Deep tendon reflexes were normal. The following diagnoses have been put forward successively: Holt-Oram syndrome, trichorhinophalangeal syndrome (in the first years his hair was sparse and thin), and Smith-Lemli-Opitz syndrome. The correct diagnosis was finally made at 9–5 years when, on occasion of a gum bleeding, investigation of the coagulation revealed the typical coagulopathy of CDG syndrome.8 Clinical examination at that time also showed small testes (1 ml).
Laboratory investigations
Normal results were obtained for peripheral blood indices and for serum electrolytes, creatinine, uric acid, amino acids, albumin, cholesterol, alkaline phosphatase, glutamic pyruvic transaminase, γ-glutamyltransaminase, IgA, IgM, transferrin, ceruloplasmin, creatine kinase, aspartate aminotransferase, coagulation factor VIII and X activities, von Willebrand factor antigen, ristocetin cofactor, fibrinogen, complement factors C1q, C3c, C4, C5, and C1 esterase inhibitor, follicle stimulating hormone, luteinizing hormone, prolactin, growth hormone, free thyroxine, total triiodothyronine, thyroid stimulating hormone, insulin, and cortisol.

Lowered serum values were found for a large number of glycoproteins (table). There was an increase of serum glutamic oxaloacetic transaminase: 80–160 U/l (normal range <40), of complement factor C3d: 32% (0–6–3%), and of the activated partial thromboplastin time: 71 seconds (24–38). There was a decrease of the thrombin time: 15 seconds (18–24), serum iron: 75 μmol/l (143–215), total thyroxine: 51.5 nmol/l (70.8–154), reverse triiodothyronine: 0.20 nmol/l (0.31–0.77), and 25-hydroxyvitamin D: 12.5 nmol/l (17.5–149.8). Routine urine analysis and concentration of cerebrospinal fluid protein were normal.

In lymphocytes activities of the lysosomal enzymes aspartate aminotransferase A, α-L-fucosidase, β-galactosidase, α-glucosidase, β-glucuronidase, N-acetyl β-hexosaminidase, and α-mannosidase were normal. Chromosomal analysis in lymphocytes and fibroblasts was normal. It has to be noted that lymphocyte culture was successful only at the seventh attempt.

Radiological examination of the skeleton showed osteopenia, luxation of the left radius, bilateral coxa valga, gracile long bones, and hemivertebra of C6. Electromyography, nerve conduction velocity, and evoked potentials gave normal results. On ophthalmological examination there were somewhat pale and hazy papillae at 9 years and decreased amplitude of the electroretinogram. Electroencephalography showed a slow basal rhythm and paroxysmal activity. Magnetic resonance imaging of the brain was normal. Liver biopsy was refused.

Methods
ISOELECTRIC FOCUSING OF SERUM TRANSFERRIN
This was performed as previously described.49

STRUCTURAL STUDIES OF SERUM TRANSFERRIN
Serum transferrin was isolated by immunofinity chromatography and transferrin subfractions were separated by ion exchange on a Mono Q HR 5/5 column using a fast protein liquid chromatography technique.10 Monosaccharide molar ratios were determined after methanolysis and trimethylsilylation.11 1H-nuclear magnetic resonance12 13 and electrospray mass spectrometry14 were performed on the isolated transferrin.

FIBROBLAST CULTURE AND ENZYME EXTRACTION
Fibroblasts were grown in 100 mm tissue culture dishes to a confluent monolayer (about 106 cells/dish) in alpha minimal essential medium (α-MEM) containing glucose, 10% fetal calf serum, antibiotics, and amphotericin. The medium was removed, the cells were washed with citrate saline EDTA (0-2%), trypsin was added to the dish, followed by 5 ml α-MEM/10% fetal calf serum when the cells were rounded up. The cells were rinsed with the same solution and centrifuged at 1000 rpm for 5 minutes. The cells were washed with 5 ml phosphate buffered saline (PBS), centrifuged at 1000 rpm for 5 minutes, the PBS was removed, and the cell pellets were frozen at −70°C. The enzyme extract was prepared by dissolving the frozen pellets in an equal volume of ice cold 0·1 M 2-[N-morpholino] ethanesulfonic acid (MES), pH 6·5, 1% Triton X-100, 0·2 M sodium chloride (NaCl), and 0·02% sodium azide. Protein concentrations were determined on the Triton extracts with the BCA Protein Assay Reagent (Pierce) using bovine serum albumin as standard.

ENZYME ASSAYS
GnT I (Uridine diphosphate (UDP)-GlcNAc:α3-6-mannoside β-1,2-N-acetylglucosaminyltransferase I; EC 2.4.1.101)
The reaction mixture in the enzyme assay15 contained, in a total volume of 0·020 ml, 0·25 mM M4-octyl (Manα1→6[Manα1→3]Manβ-octyl), used in the laboratory of Professor H Paulsen, Hamburg, Germany), 0·1 M MES, pH 6·5, 0·1 M NaCl, 20 mM manganese chloride, 0·5 mM UDP-[3H]GlcNAc (10000 disintegrations/minute (dpm)/nmol), 0·25% Triton X-100, 10 mM AMP, 0·2 M GlcNAc, 0·02% sodium azide, and enzyme extract (0·1–0·3 mg). After incubation at 37°C for 30–60 minutes, the reaction was stopped with 0·5 ml water and frozen at −70°C. Product formation was assayed by adsorption to Sep-Pak C18 reverse phase cartridges (Waters), elution with 3·0 ml methanol16 and scintillation counting. Values were corrected for radioactivity obtained in control incubations lacking acceptor substrate.

GnT II (UDP-GlcNAc:a6-6-mannoside β-1,2-N-acetylglucosaminyltransferase II; EC 2.4.1.143)
Exactly as for GnT I17 18 except that the substrate is 0·25 mM MnM4-octyl (Manα1→6[Manα1→3]Manβ-octyl), synthesised in the laboratory of Professor H Paulsen, Hamburg, Germany).

GalT (UDP-Gal:GlcNAc β-1,4-galactosyltransferase; EC 2.4.1.38/90)
The reaction mixture in the enzyme assay contains, in a total volume of 0·020 ml, 20 mM GlcNAc, 0·1 M MES, pH 6·5, 0·1 M NaCl, 20 mM manganese chloride, 4·0 mM UDP-[3H]Gal (660 dpm/nmol), 0·25% Triton
Carbohydrate deficient glycoprotein syndrome type II: a deficiency in Golgi localised N-acetyl-glucosaminyltransferase II

Transferrin: a protein that transports iron in the blood.

**Figure 1** Isoelectric focusing pattern of serum transferrin in controls (C), CDG syndrome type I (I) and in both patients with CDG syndrome type II (II1 and II2).

X-100, 0.02% sodium azide, and enzyme extract (0.1–0.3 mg). After incubation at 37°C for 30 minutes, the reaction was stopped with 0.5 ml water and frozen at –70°C. Product formation was assayed by passing the reaction mixture through a 1 ml column of AG 1-X8 (chloride form) equilibrated with water. The column was washed with 2 ml water and the radioactivity in the eluate was counted in scintillation fluid. Values are corrected for radioactivity obtained in control incubations lacking acceptor substrate.

**Results**

Isoelectric focusing of serum transferrin of the patient showed a markedly abnormal pattern (fig 1). Compared with controls tetrasiolotransferrin was nearly absent. There was a large increase of disialotransferrin, and a band was present at the monosialotransferrin position as well as a faint additional (unidentified) band between the position of monosialotransferrin and asialotransferrin. The parents of the patient showed a normal pattern. Type I patients show a distinctly different pattern with a less pronounced decrease of tetrasialotransferrin, smaller increase of disialotransferrin, no additional band, and an important asialotransferrin fraction (fig 1), while type III patients show an approximately equal increase of tri-, di-, mono- and asialotransferrin with appreciable amounts of normal isoforms.

Figure 2A shows the structures of the two N-glycans previously found in serum tetrasialotransferrin from normal controls.

Analysis by 1H-nuclear magnetic resonance and electropray mass spectrometry of purified disialotransferrin from the patient showed the presence of two truncated monoantennary monosialylated N-glycans per mole of transferrin (fig 2B). The difference between the molecular weights of normal serum tetrasialotransferrin (79 588) and disialotransferrin from the patient (78 272) indicates that two moles of the trisaccharide chain α-NeuAc(2-→6)β-D-Gal(1→4)β-D-GlcNAc are missing per mole of transferrin.

The activities (expressed as nmol/mg/hour) of GnT I (5.3, 5.7 respectively) and Gal T (17, 18 respectively) in fibroblast extracts from the present patient and the previously reported patient were in the normal range while GnT II activities in these extracts were respectively 1.4 and 0.9% of the mean activity in control fibroblast extracts (patients: 0.03, 0.02, respectively; controls 2.2±1.0; n=4 or more for all assays). GnT II assays carried out on mixtures of Triton X-100 extracts from control and patient fibroblasts indicated that the almost complete absence of enzyme activity in the patient extracts was not due to the presence of an enzyme inhibitor.

**Discussion**

The present patient and a recently reported Iranian child show a very similar CDG syndrome with, however, some clinical and biochemical differences from the classic picture. We have therefore proposed to label this CDG syndrome type II as opposed to type I in the other patients. More specifically, both patients have a more severe psychomotor retardation, no peripheral neuropathy, and a normal cerebellum on magnetic resonance imaging. They show a stereotypic
handwashing behaviour as seen in Rett’s syndrome. Both have a ventricular septal defect and this was also present in a deceased sibling of the Iranian patient who very probably had the same syndrome. We have of course to wait for a larger number of patients to know if this is part of the syndrome or just a coincidence.

Biochemical differences from CDG syndrome type I are the absence of proteinuria, no increase of serum glutamatic pyruvic transaminase, normal serum albumin concentrations, deficiency of clotting factor XII (in addition to the classic pattern with deficiency of factor XI and, sometimes, of factor IX, as well as antithrombin III, heparin cofactor II, protein C and protein S), transiently decreased serum IgG, a normal activity in serum of arylsulphatase A, and a decreased activity of β-glucuronidase (table). They show a specific isoelectric focusing pattern of serum hexosaminidase A, and of sialotransferrins with near absence of tetra- and sialotransferrins, and a marked increase of disialotransferrin (fig 1).

The glycan structure of serum disialotransferrin, determined in the present patient, was similar to that of the monantennary N-acetyllactosamine type glycan accumulating in erythrocytes from patients with congenital dyserythropoietic anaemia type II (HEMPAS) and differed from the structure of the disialylated diantennary and the triasialylated triantennary N-acetyllactosamine type glycan previously reported in normal serum transferrin. Lymphocyte extracts from two HEMPS patients were reported to have GnT II activities at 11% and 30% of normal values. The same enzymatic defect was therefore postulated to be present in CDG syndrome type II. We were able to confirm our hypothesis by showing a severe deficiency of N-acetylgalactosaminyltransferase II in fibroblasts of the present and the previously reported patient.

The common (Man)3y(GlcNAc)2-Asn core structure of complex N-glycans is substituted with branches or antennae which are initiated by the sequential action of six N-acetylgalactosaminyltransferases (GlcNAc-transferases I–VI), GnT II catalyses the conversion of Manα1→6[Glcnacβ1→2Manα1→3]Manβ-R to Glcnacβ1→2Manα1→6[Glcnacβ1→2Manα1→3]Manβ-R where R is 1→4GlcNacβ1→4 GlcNac-Asn-X. Prior GnT I action is essential for the actions of GnT II, III, and IV whereas prior GnT II action is essential for the action of GnT V; complex N-glycan synthesis cannot occur until GnT I and II have acted. Patients lacking GnT II will therefore be unable to add any GlcNAc residues to the Manα1→6 arm of the N-glycan core. However, the substrate of N-acetylgalactosaminyltransferase II can be further glycosylated by galactosyltransferase and sialyltransferase on the single antenna containing N-acetylgalactosamine (fig 3). This monosialoglycan is present twice on the transferrin protein thus resulting in the disialotransferrin fraction as shown.

The human GnT II gene (MGAT2) has
been cloned and is on chromosome 14q21.26

Genetic analysis of the CDG syndrome type II fibroblasts with human GnT II probes is under way.

In conclusion, this is the first of the three known CDG syndrome types whose basic defect has been elucidated.

We thank Miss E Jansen for expert technical assistance, Professor Jean-Jacques Cassiman, Leuven, Belgium, for cultivating the fibroblasts, and Professor Jos Kint, Ghent, Belgium, for determination of lysosomal enzyme activities in serum and lymphocytes. This work was supported by the Belgian Nationaal Fonds voor Wetenschappelijk Onderzoek (grant 3.015.94), the Université des Sciences et Technologies de Lille and the Centre National de la Recherche Scientifique (Unité Mixte de Recherche No 111, Director Professor André Verbist) (grant INSEM 930507).

Carbohydrate deficient glycoprotein syndrome type II: a deficiency in Golgi localised N-acetyl-glucosaminyltransferase II.
J Jaeken, H Schachter, H Carchon, P De Cock, B Coddeville and G Spik

Arch Dis Child 1994 71: 123-127
doi: 10.1136/adc.71.2.123

Updated information and services can be found at:
http://adc.bmj.com/content/71/2/123

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/